We have specifically prescribed a short (2 weeks) intervention before IFN-α therapy, in order to potentially correct the lower omega-3 fatty acid levels that we had previously identified as a risk factor for the development of IFN-α-induced depression [5]. The gene discussed is IFNA1; the disease is major depressive disorder.